Selecta Biosciences, Inc.

Release Summary

Selecta Biosciences, Inc. announced the dosing of the first patient in the Company’s Phase 1b clinical trial of SEL-212, Selecta’s proprietary biologic treatment for refractory and tophaceous gout.